What is BiomX?
BiomX is at the forefront of microbiome therapeutics, focusing on the development of both natural and engineered phage cocktails. These advanced biological agents are designed to precisely target and eliminate specific bacteria implicated in a range of chronic and debilitating conditions. The company's pipeline targets significant unmet medical needs, including cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. By identifying proprietary bacterial targets and customizing phage compositions, BiomX aims to offer a new class of treatments that address the root causes of these diseases.
How much funding has BiomX raised?
BiomX has raised a total of $71.3M across 4 funding rounds:
Series A
$24M
Series B
$32M
Other Financing Round
$12M
Private Equity
$3.3M
Series A (2017): $24M with participation from Takeda Ventures, JJDC, and OrbiMed
Series B (2019): $32M, investors not publicly disclosed
Other Financing Round (2025): $12M supported by Cystic Fibrosis Foundation
Private Equity (2026): $3.3M, investors not publicly disclosed
Key Investors in BiomX
Takeda Ventures
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company, a global, R&D-driven biopharmaceutical leader. They focus on investing in innovative companies that align with Takeda's strategic interests in areas such as oncology, rare diseases, neuroscience, and gastroenterology, aiming to foster external innovation.
JJDC
While the provided domain points to an educational institution, in the context of this funding round, JJDC likely represents a distinct investment entity or a misattributed data point. Without further clarification, its specific investment focus remains undisclosed.
OrbiMed
OrbiMed is a leading global investment firm dedicated exclusively to the healthcare sector. They manage capital across a spectrum of healthcare companies, from early-stage biopharmaceuticals and medical devices to established healthcare services, leveraging deep industry expertise to drive growth and innovation.
What's next for BiomX?
The substantial enterprise-level funding and strategic investment indicate BiomX is poised for significant scaling and advancement of its clinical programs. This capital infusion will likely accelerate the progression of its phage cocktail candidates through clinical trials, potentially bringing them closer to regulatory approval and commercialization. The company's focus on complex chronic diseases suggests a long-term development strategy, with future financing rounds expected to support late-stage trials and market entry. BiomX's trajectory points towards becoming a key player in the burgeoning field of microbiome-based medicine.
See full BiomX company page
